From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: BDEV

Search articles by EPIC code

The volatile and excitable world of Barratt Developments (and other home builders)

It is always interesting times in the world’s financial markets, but sometimes it is more interesting than average. And as for sectors and stocks, Barratt Developments (BDEV) is one of the more fascinating names in the FTSE 100 at the moment given the obsession with the housing sector and the company’s over 50% share price fall year-to-date. And it is probably a good thing that I do not own the stock myself as it is down a further 5% this morning after publishing a trading update.


The latest homebuilder sector excitements from Barratt Developments

I am certain that there are a bunch of people who are excited that the latest house prices from Halifax showed a 0.4% increase in August, meaning (apparently) average UK house prices from this source were up 11.5% year-on-year. How pleasant statistically, but it is all looking in the past and what really matters, about the housing market and so much more in life, is what happens next. And that nicely brings us onto today’s full year numbers from Barratt Developments (BDEV).


Barratt Boosts Business in Spite of Headwinds and should Build its Share Price

Hello Share Grumblers. It becomes ever harder for a bull trader like myself to find possible winners as the Footsie drops further week by week. But there are some promising sectors out there. And those, despite reservations from Uncle Tom, look to me to include the house building game. Take Barratt Developments (BDEV) for example. It sold nearly 18,000 homes in its latest year.


Thursday analytical insights with Barratt Developments and Ashmore Group

If I had to bet, then I would say that Thursday is the busiest analytical day for any investor, analyst or fund manager. There is a different angle today however in a bunch of UK numbers: trading updates for the period ended 30th June, which are fully responded too in September. Such (future) excitement! First up is Barratt Developments (BDEV), the homebuilder whose shares I am sure many of you may own but I don’t think I ever have.


I bet Barratt’s chairman wishes it was already (permanent) personal holiday time

You may have heard the other day that the latest Nationwide house price survey observed that apparently annual house prices rose by 11.2% in May, making the average UK home costs £269,914…or a mere 6.9 times average earnings.  I am sure many people are excited about this but most probably know the reality of significantly slowing - if any! - house price growth over full year 2022.  Spot the impact of higher interest rates and a slowing economy… And on possibly related factors I read in the press today that the “titan housebuilder Barratt (BDEV) is planning to begin a search for a new chairman, with City grandee John Allan to step down”. 


Whilst I wait for GlaxoSmithKline to split itself…more on the UK housing market via Barratt Developments

I am looking forward to the GlaxoSmithKline (GSK) conference call later today. Whilst technically it is focused on the full year 2021 numbers out earlier today (which showed rising sales and falling profits), far more important is the confirmation that it is ‘on track to demerge a new world-leading Consumer Healthcare business mid-2022’. Last month I was amused by the (ultimately unsuccessful) partial bid approach by Unilever (ULVR) but my instinct is that the Pharmaceutical / Vaccines business is still underappreciated going forward. I was certainly pleased to see the ‘pipeline of 21 vaccines and 43 medicines’ angles and I do wonder - when the business split occurs in a few months time - whether not only retaining but adding to this part of the business. Something to be more thoughtful about later this year whilst, despite the excellent total return performance over the last year, I remain a strong HOLDer. So whilst I continue to hang onto my GlaxoSmithKline shares…what do I make of today’s interim results announcement from FTSE 100 housebuilder Barratt Developments (BDEV)?...

Page 1 of 8 (72 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments